Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site

R. M. Hartley, J. Peng, G. A. Fest, S. Dakshanamurthy, D. E. Frantz, M. L. Brown, Susan L Mooberry

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Bioassay-guided fractionation was used to isolate the lignan polygamain as the microtubule-active constituent in the crude extract of the Mountain torchwood, Amyris madrensis. Similar to the effects of the crude plant extract, polygamain caused dose-dependent loss of cellular microtubules and the formation of aberrant mitotic spindles that led to G 2/M arrest. Polygamain has potent antiproliferative activities against a wide range of cancer cell lines, with an average IC 50 of 52.7 nM. Clonogenic studies indicate that polygamain effectively inhibits PC-3 colony formation and has excellent cellular persistence after washout. In addition, polygamain is able to circumvent two clinically relevant mechanisms of drug resistance, the expression of P-glycoprotein and the βIII isotype of tubulin. Studies with purified tubulin show that polygamain inhibits the rate and extent of purified tubulin assembly and displaces colchicine, indicating a direct interaction of polygamain within the colchicine binding site on tubulin. Polygamain has structural similarities to podophyllotoxin, and molecular modeling simulations were conducted to identify the potential orientations of these compounds within the colchicine binding site. These studies suggest that the benzodioxole group of polygamain occupies space similar to the trimethoxyphenyl group of podophyllotoxin but with distinct interactions within the hydrophobic pocket. Our results identify polygamain as a new microtubule destabilizer that seems to occupy a unique pharmacophore within the colchicine site of tubulin. This new pharmacophore will be used to design new colchicine site compounds that might provide advantages over the current agents.

Original languageEnglish (US)
Pages (from-to)431-439
Number of pages9
JournalMolecular Pharmacology
Volume81
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Colchicine
Microtubules
Tubulin
Podophyllotoxin
Complex Mixtures
Binding Sites
polygamain
Lignans
Spindle Apparatus
Plant Extracts
P-Glycoprotein
Hydrophobic and Hydrophilic Interactions
Drug Resistance
Biological Assay
Cell Line

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site. / Hartley, R. M.; Peng, J.; Fest, G. A.; Dakshanamurthy, S.; Frantz, D. E.; Brown, M. L.; Mooberry, Susan L.

In: Molecular Pharmacology, Vol. 81, No. 3, 03.2012, p. 431-439.

Research output: Contribution to journalArticle

Hartley, R. M. ; Peng, J. ; Fest, G. A. ; Dakshanamurthy, S. ; Frantz, D. E. ; Brown, M. L. ; Mooberry, Susan L. / Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site. In: Molecular Pharmacology. 2012 ; Vol. 81, No. 3. pp. 431-439.
@article{6fdd91a5b0cb41a3aecd58f5133b26e9,
title = "Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site",
abstract = "Bioassay-guided fractionation was used to isolate the lignan polygamain as the microtubule-active constituent in the crude extract of the Mountain torchwood, Amyris madrensis. Similar to the effects of the crude plant extract, polygamain caused dose-dependent loss of cellular microtubules and the formation of aberrant mitotic spindles that led to G 2/M arrest. Polygamain has potent antiproliferative activities against a wide range of cancer cell lines, with an average IC 50 of 52.7 nM. Clonogenic studies indicate that polygamain effectively inhibits PC-3 colony formation and has excellent cellular persistence after washout. In addition, polygamain is able to circumvent two clinically relevant mechanisms of drug resistance, the expression of P-glycoprotein and the βIII isotype of tubulin. Studies with purified tubulin show that polygamain inhibits the rate and extent of purified tubulin assembly and displaces colchicine, indicating a direct interaction of polygamain within the colchicine binding site on tubulin. Polygamain has structural similarities to podophyllotoxin, and molecular modeling simulations were conducted to identify the potential orientations of these compounds within the colchicine binding site. These studies suggest that the benzodioxole group of polygamain occupies space similar to the trimethoxyphenyl group of podophyllotoxin but with distinct interactions within the hydrophobic pocket. Our results identify polygamain as a new microtubule destabilizer that seems to occupy a unique pharmacophore within the colchicine site of tubulin. This new pharmacophore will be used to design new colchicine site compounds that might provide advantages over the current agents.",
author = "Hartley, {R. M.} and J. Peng and Fest, {G. A.} and S. Dakshanamurthy and Frantz, {D. E.} and Brown, {M. L.} and Mooberry, {Susan L}",
year = "2012",
month = "3",
doi = "10.1124/mol.111.075838",
language = "English (US)",
volume = "81",
pages = "431--439",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site

AU - Hartley, R. M.

AU - Peng, J.

AU - Fest, G. A.

AU - Dakshanamurthy, S.

AU - Frantz, D. E.

AU - Brown, M. L.

AU - Mooberry, Susan L

PY - 2012/3

Y1 - 2012/3

N2 - Bioassay-guided fractionation was used to isolate the lignan polygamain as the microtubule-active constituent in the crude extract of the Mountain torchwood, Amyris madrensis. Similar to the effects of the crude plant extract, polygamain caused dose-dependent loss of cellular microtubules and the formation of aberrant mitotic spindles that led to G 2/M arrest. Polygamain has potent antiproliferative activities against a wide range of cancer cell lines, with an average IC 50 of 52.7 nM. Clonogenic studies indicate that polygamain effectively inhibits PC-3 colony formation and has excellent cellular persistence after washout. In addition, polygamain is able to circumvent two clinically relevant mechanisms of drug resistance, the expression of P-glycoprotein and the βIII isotype of tubulin. Studies with purified tubulin show that polygamain inhibits the rate and extent of purified tubulin assembly and displaces colchicine, indicating a direct interaction of polygamain within the colchicine binding site on tubulin. Polygamain has structural similarities to podophyllotoxin, and molecular modeling simulations were conducted to identify the potential orientations of these compounds within the colchicine binding site. These studies suggest that the benzodioxole group of polygamain occupies space similar to the trimethoxyphenyl group of podophyllotoxin but with distinct interactions within the hydrophobic pocket. Our results identify polygamain as a new microtubule destabilizer that seems to occupy a unique pharmacophore within the colchicine site of tubulin. This new pharmacophore will be used to design new colchicine site compounds that might provide advantages over the current agents.

AB - Bioassay-guided fractionation was used to isolate the lignan polygamain as the microtubule-active constituent in the crude extract of the Mountain torchwood, Amyris madrensis. Similar to the effects of the crude plant extract, polygamain caused dose-dependent loss of cellular microtubules and the formation of aberrant mitotic spindles that led to G 2/M arrest. Polygamain has potent antiproliferative activities against a wide range of cancer cell lines, with an average IC 50 of 52.7 nM. Clonogenic studies indicate that polygamain effectively inhibits PC-3 colony formation and has excellent cellular persistence after washout. In addition, polygamain is able to circumvent two clinically relevant mechanisms of drug resistance, the expression of P-glycoprotein and the βIII isotype of tubulin. Studies with purified tubulin show that polygamain inhibits the rate and extent of purified tubulin assembly and displaces colchicine, indicating a direct interaction of polygamain within the colchicine binding site on tubulin. Polygamain has structural similarities to podophyllotoxin, and molecular modeling simulations were conducted to identify the potential orientations of these compounds within the colchicine binding site. These studies suggest that the benzodioxole group of polygamain occupies space similar to the trimethoxyphenyl group of podophyllotoxin but with distinct interactions within the hydrophobic pocket. Our results identify polygamain as a new microtubule destabilizer that seems to occupy a unique pharmacophore within the colchicine site of tubulin. This new pharmacophore will be used to design new colchicine site compounds that might provide advantages over the current agents.

UR - http://www.scopus.com/inward/record.url?scp=84863401577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863401577&partnerID=8YFLogxK

U2 - 10.1124/mol.111.075838

DO - 10.1124/mol.111.075838

M3 - Article

C2 - 22169850

AN - SCOPUS:84863401577

VL - 81

SP - 431

EP - 439

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -